| Mrs Claudia Renee Rivard, LPN | |
|
58 Stage Rd, Deerfield, NH 03037-1607 | |
| (603) 463-9018 | |
| Not Available |
| Full Name | Mrs Claudia Renee Rivard |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 58 Stage Rd, Deerfield, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205980612 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 010321-22 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Claudia Renee Rivard, LPN 58 Stage Rd, Deerfield, NH 03037-1607 Ph: (603) 463-9018 | Mrs Claudia Renee Rivard, LPN 58 Stage Rd, Deerfield, NH 03037-1607 Ph: (603) 463-9018 |
News Archive
NanoLogix Inc. (NNLX), an innovator in the rapid detection, identification and determination of antibiotic resistance and sensitivity of live bacteria, announces that the State of Ohio Department of Economic Development's International Trade Assistance Center (ITAC) based at Youngstown State University (YSU) is providing support to Hubbard Ohio-based NanoLogix Inc. for international distribution of NanoLogix products by Nasaem Al-Jazira, a Saudi Arabian Trading and Distribution Company.
A solar eclipse doesn't occur every day, so it's good to be reminded how to watch one safely. Wichita State University's Greg Novacek offers the following tips on how to watch a solar eclipse safely.
Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome - part of acute radiation syndrome (ARS) - for military personnel, first responders and the general public. The Einstein research, funded by the federal Centers for Medical Countermeasures Against Radiation, is part of a program coordinated by the National Institute of Allergy and Infectious Diseases.
Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.
› Verified 7 days ago